<p>Prime Medicine, Inc. (NYSE:PRME - 獲取免費報告) 的股價在週三交易中上漲了 7.5%。該股最高交易價格為 4.05 美元，最後交易價格為 3.9770 美元。在午盤交易中，成交量為 2,350,337 股，較平均交易量 3,235,643 股下降了 27%。該股此前收盤價為 3.70 美元。</p>
<p>獲取 <strong>Prime Medicine</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>2024 年值得關注的兩隻基因編輯股票</li>
</ul>
<p>幾家研究公司最近對 PRME 發佈了報告。花旗集團將 Prime Medicine 的目標股價從 5.00 美元下調至 4.25 美元，並在 11 月 11 日的研究報告中對該股給予了 “中性” 評級。Chardan Capital 將 Prime Medicine 的目標股價從 10.00 美元下調至 9.00 美元，並在 11 月 10 日的報告中給予該股 “買入” 評級。Lifesci Capital 在 12 月 23 日的研究報告中開始覆蓋 Prime Medicine，給予 “跑贏大盤” 評級，目標股價為 6.00 美元。最後，Wedbush 在 11 月 10 日的研究報告中重申了 “跑贏大盤” 評級，並將 Prime Medicine 的目標股價設定為 8.00 美元。四位分析師對該股給予了買入評級，三位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，Prime Medicine 目前的共識評級為 “適度買入”，共識目標股價為 7.21 美元。</p>
<p><strong>閲讀我們關於 PRME 的最新研究報告</strong></p>
<h2>Prime Medicine 股價上漲 10.9%</h2>
<p>該公司的 50 日簡單移動平均線為 3.81 美元，200 日簡單移動平均線為 4.14 美元。該股市值為 7.41 億美元，市盈率為-2.00，貝塔值為 2.71。</p>
<h2>對 Prime Medicine 的對沖基金觀點</h2>
<p>一些機構投資者和對沖基金最近買入和賣出了 PRME 的股票。Alphabet Inc.在第三季度將其在 Prime Medicine 的股份增加了 10.0%。Alphabet Inc.目前擁有 16,562,498 股該公司的股票，價值 91,756,000 美元，此前在上個季度購買了額外的 1,500,000 股。ARK Investment Management LLC 在第三季度將其在 Prime Medicine 的持股增加了 135.8%。ARK Investment Management LLC 目前擁有 5,477,851 股該公司的股票，價值 30,347,000 美元，此前在上個季度購買了額外的 3,155,182 股。Vanguard Group Inc.在第三季度將其在 Prime Medicine 的持股增加了 35.7%。Vanguard Group Inc.目前擁有 4,921,865 股該公司的股票，價值 27,267,000 美元，此前在該期間購買了額外的 1,294,355 股。Farallon Capital Management LLC 在第三季度將其在 Prime Medicine 的持股增加了 533.3%。Farallon Capital Management LLC 目前擁有 4,750,000 股該公司的股票，價值 26,315,000 美元，此前在上個季度收購了額外的 4,000,000 股。最後，Sumitomo Mitsui Trust Group Inc.在第三季度將其在 Prime Medicine 的持股增加了 127.7%。Sumitomo Mitsui Trust Group Inc.目前擁有 3,629,924 股該公司的股票，價值 20,110,000 美元，此前在該期間收購了額外的 2,035,406 股。機構投資者和對沖基金持有該公司 70.37% 的股份。</p>
<h2>關於 Prime Medicine</h2>
<p>(獲取免費報告)</p>
<p>Prime Medicine, Inc. NYSE: PRME 是一家臨牀階段的基因治療公司，專注於利用先進的 CRISPR 衍生基因編輯技術——原編輯的潛力。通過完善精確修正致病突變所需的工具，Prime Medicine 旨在開發針對疾病潛在遺傳驅動因素的單劑量治療。該公司應用其專有的工程和遞送平台，以優化靶向效率並最小化非靶向效應，使其在下一代基因編輯治療領域處於領先地位。</p>
<p>Prime Medicine 的研發工作涵蓋多個治療領域，包括罕見遺傳疾病、免疫腫瘤學和自身免疫疾病。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Prime Medicine</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>請勿刪除，立即閲讀</li>
<li>你還認為白銀是個笑話嗎？看看接下來會發生什麼。</li>
<li>將這些代碼輸入你的普通經紀賬户</li>
<li>這隻股票獲得 94 分（滿分 100 分）</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
<p>在你考慮 Prime Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Prime Medicine 並不在名單上。</p>
<p>雖然 Prime Medicine 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PRME

<p>Prime Medicine (NYSE:PRME) 的股價上漲了 7.5%，達到 3.9770 美元，交易量為 2,350,337 股。分析師們的看法不一，花旗集團將其目標價從 5.00 美元下調至 4.25 美元，而 Chardan Capital 則設定了 9.00 美元的目標價。機構投資者持有該股票的 70.37%，包括 Alphabet Inc.和 ARK Investment Management 等公司的持股顯著增加。Prime Medicine 專注於先進的基因編輯技術，旨在開發針對遺傳疾病和其他疾病的治療方案</p>

<p>Prime Medicine, Inc. (NYSE:PRME - Get Free Report)'s stock price traded up 7.5% during trading on Wednesday . The stock traded as high as $4.05 and last traded at $3.9770. 2,350,337 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 3,235,643 shares. The stock had previously closed at $3.70.</p>
<div class="lb-trans"><p>Prime Medicine, Inc. (NYSE:PRME - 獲取免費報告) 的股價在週三交易中上漲了 7.5%。該股最高交易價格為 4.05 美元，最後交易價格為 3.9770 美元。在午盤交易中，成交量為 2,350,337 股，較平均交易量 3,235,643 股下降了 27%。該股此前收盤價為 3.70 美元。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Prime Medicine</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>2 gene editing stocks to keep on your 2024 watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年值得關注的兩隻基因編輯股票</li>
</ul>
</div><p>Several research firms recently issued reports on PRME. Citigroup reduced their price target on shares of Prime Medicine from $5.00 to $4.25 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday, November 11th. Chardan Capital reduced their target price on Prime Medicine from $10.00 to $9.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, November 10th. Lifesci Capital initiated coverage on Prime Medicine in a research note on Tuesday, December 23rd. They issued an &#34;outperform&#34; rating and a $6.00 price target on the stock. Finally, Wedbush restated an &#34;outperform&#34; rating and set a $8.00 price objective on shares of Prime Medicine in a research report on Monday, November 10th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Prime Medicine presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $7.21.</p>
<div class="lb-trans"><p>幾家研究公司最近對 PRME 發佈了報告。花旗集團將 Prime Medicine 的目標股價從 5.00 美元下調至 4.25 美元，並在 11 月 11 日的研究報告中對該股給予了 “中性” 評級。Chardan Capital 將 Prime Medicine 的目標股價從 10.00 美元下調至 9.00 美元，並在 11 月 10 日的報告中給予該股 “買入” 評級。Lifesci Capital 在 12 月 23 日的研究報告中開始覆蓋 Prime Medicine，給予 “跑贏大盤” 評級，目標股價為 6.00 美元。最後，Wedbush 在 11 月 10 日的研究報告中重申了 “跑贏大盤” 評級，並將 Prime Medicine 的目標股價設定為 8.00 美元。四位分析師對該股給予了買入評級，三位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，Prime Medicine 目前的共識評級為 “適度買入”，共識目標股價為 7.21 美元。</p>
</div><p><strong>Read Our Latest Research Report on PRME</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 PRME 的最新研究報告</strong></p>
</div><h2>Prime Medicine Stock Up 10.9%</h2>
<div class="lb-trans"><h2>Prime Medicine 股價上漲 10.9%</h2>
</div><p>The business's 50 day simple moving average is $3.81 and its two-hundred day simple moving average is $4.14. The stock has a market cap of $741.00 million, a P/E ratio of -2.00 and a beta of 2.71.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 3.81 美元，200 日簡單移動平均線為 4.14 美元。該股市值為 7.41 億美元，市盈率為-2.00，貝塔值為 2.71。</p>
</div><h2>Hedge Funds Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>對 Prime Medicine 的對沖基金觀點</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of PRME. Alphabet Inc. boosted its stake in shares of Prime Medicine by 10.0% during the third quarter. Alphabet Inc. now owns 16,562,498 shares of the company's stock valued at $91,756,000 after purchasing an additional 1,500,000 shares in the last quarter. ARK Investment Management LLC raised its holdings in Prime Medicine by 135.8% in the 3rd quarter. ARK Investment Management LLC now owns 5,477,851 shares of the company's stock valued at $30,347,000 after buying an additional 3,155,182 shares during the last quarter. Vanguard Group Inc. boosted its position in Prime Medicine by 35.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,921,865 shares of the company's stock worth $27,267,000 after buying an additional 1,294,355 shares during the period. Farallon Capital Management LLC grew its holdings in Prime Medicine by 533.3% during the 3rd quarter. Farallon Capital Management LLC now owns 4,750,000 shares of the company's stock worth $26,315,000 after acquiring an additional 4,000,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in Prime Medicine by 127.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,629,924 shares of the company's stock valued at $20,110,000 after acquiring an additional 2,035,406 shares during the period. Institutional investors and hedge funds own 70.37% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近買入和賣出了 PRME 的股票。Alphabet Inc.在第三季度將其在 Prime Medicine 的股份增加了 10.0%。Alphabet Inc.目前擁有 16,562,498 股該公司的股票，價值 91,756,000 美元，此前在上個季度購買了額外的 1,500,000 股。ARK Investment Management LLC 在第三季度將其在 Prime Medicine 的持股增加了 135.8%。ARK Investment Management LLC 目前擁有 5,477,851 股該公司的股票，價值 30,347,000 美元，此前在上個季度購買了額外的 3,155,182 股。Vanguard Group Inc.在第三季度將其在 Prime Medicine 的持股增加了 35.7%。Vanguard Group Inc.目前擁有 4,921,865 股該公司的股票，價值 27,267,000 美元，此前在該期間購買了額外的 1,294,355 股。Farallon Capital Management LLC 在第三季度將其在 Prime Medicine 的持股增加了 533.3%。Farallon Capital Management LLC 目前擁有 4,750,000 股該公司的股票，價值 26,315,000 美元，此前在上個季度收購了額外的 4,000,000 股。最後，Sumitomo Mitsui Trust Group Inc.在第三季度將其在 Prime Medicine 的持股增加了 127.7%。Sumitomo Mitsui Trust Group Inc.目前擁有 3,629,924 股該公司的股票，價值 20,110,000 美元，此前在該期間收購了額外的 2,035,406 股。機構投資者和對沖基金持有該公司 70.37% 的股份。</p>
</div><h2>About Prime Medicine</h2>
<div class="lb-trans"><h2>關於 Prime Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Prime Medicine, Inc NYSE: PRME is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.</p>
<div class="lb-trans"><p>Prime Medicine, Inc. NYSE: PRME 是一家臨牀階段的基因治療公司，專注於利用先進的 CRISPR 衍生基因編輯技術——原編輯的潛力。通過完善精確修正致病突變所需的工具，Prime Medicine 旨在開發針對疾病潛在遺傳驅動因素的單劑量治療。該公司應用其專有的工程和遞送平台，以優化靶向效率並最小化非靶向效應，使其在下一代基因編輯治療領域處於領先地位。</p>
</div><p>Prime Medicine's research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.</p>
<div class="lb-trans"><p>Prime Medicine 的研發工作涵蓋多個治療領域，包括罕見遺傳疾病、免疫腫瘤學和自身免疫疾病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>This stock gets a 94 out of 100</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Prime Medicine</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>請勿刪除，立即閲讀</li>
<li>你還認為白銀是個笑話嗎？看看接下來會發生什麼。</li>
<li>將這些代碼輸入你的普通經紀賬户</li>
<li>這隻股票獲得 94 分（滿分 100 分）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Prime Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Prime Medicine 並不在名單上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prime Medicine 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Prime Medicine（NYSE:PRME）股價上漲 7.5% - 接下來會如何發展？